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Benefits of the Implantable Cardioverter-Defibrillator
Andrew E. Epstein, MD, FACC
Birmingham, Alabama
The state-of-the-art review by Tung and colleagues provides a thoughtful perspective on balancing the benefits
and risks of implantable cardioverter-defibrillator (ICD) therapy addressing the concerns of many caring physi-
cians. In this response: 1) the clinical benefits of ICD therapy are reviewed using the evidence base resulting
from controlled clinical trials; 2) untoward effects of ICDs on quality of life are acknowledged, and it is argued
that they do not negate the results of studies in which the aggregate show benefit; and 3) cost-effectiveness of
ICD therapy is considered. Although clinical trials evaluating ICD therapy have limitations, there are few interven-
tions in which multiple trial settings have consistently over a 10-year period produced a 20% to 30% reduction
in total mortality. Research to better identify patients expected to benefit from ICD therapy is ongoing, but at
present we have the results of clinical trials that show improved survival in a broad selection of patients with left
ventricular dysfunction and either demonstrated or anticipated risk for arrhythmic death. Evidence-based medi-
cine; the rigorous process of guideline writing, review, and approval; and the ethical consideration of offering
proven life-prolonging therapies to all patients provide a compelling rationale for clinicians to carefully consider
guidelines in their clinical decision making. Updates in the new Device-Based Therapy Guidelines for the implan-
tation of ICDs and pacemakers advance these goals. (J Am Coll Cardiol 2008;52:1122–7) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.035p
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ohe state-of-the-art review by Tung et al. (1) provides a
houghtful perspective on balancing the benefits and risks of
mplantable cardioverter-defibrillator (ICD) therapy ad-
ressing the concerns of many caring physicians. It also
rovides the opportunity to emphasize the imperative of
racticing evidence-based medicine, the importance of bal-
nce in the interpretation of clinical trial results, and how
pdates in the new Device-Based Therapy Guidelines for
he implantation of ICDs and pacemakers advance these
oals (2).
Tung et al. (1) suggest that: 1) the clinical benefit of ICD
herapy has been overestimated in clinical trials; 2) the adverse
ffects on morbidity, quality of life, and the potential for
roarrhythmia has been underestimated; and 3) unfavorable
ost-effectiveness of ICD therapy is understated. In this re-
ponse these issues will be addressed using the evidence base
esulting from controlled clinical trials and rigorously devel-
ped evidence-based practice guidelines (Fig. 1).
as the Clinical Benefit
f ICD Therapy Been Overestimated?
he design of clinical trials in arrhythmia therapy has
ndergone revolutionary change in the last 2 decades. The
AST (Cardiac Arrhythmia Suppression Trial) study high-
ighted the pitfalls of not only surrogate end points (e.g.,
rom the Division of Cardiovascular Disease, Department of Medicine, Universitys
f Alabama at Birmingham, Birmingham, Alabama.
Manuscript received May 28, 2008, accepted June 12, 2008.remature ventricular contractions [PVCs]), but also of
ctive control groups (3). Although PVCs were suppressed,
ortality was increased by antiarrhythmic drug therapy.
urthermore, since the 1-year mortality was generally con-
idered to be about 10% in patients with PVCs at the time
he CAST trial was done, the 5% mortality rate in the
AST trial patients treated with antiarrhythmic drugs
ould have been judged to indicate a dramatic beneficial
ffect had there not been a randomized, blinded control
roup. Thus, the admonition by Tung et al. (1) regarding
roblems with “control” arms is well taken. Indeed, all
rimary prevention trials should incorporate a placebo
ontrol. In the 2 trials of ICD therapy that incorporated
placebo” control groups, the fact that antiarrhythmic ther-
py performed worse than optimized medical therapy may
e considered disappointing, but not necessarily unexpected.
hat “no formal comparison was commented upon” does
ot detract from these studies’ overall findings. As elegantly
hown by Myerburg et al. (4), without a placebo control as
point of reference, when 2 active interventions are com-
ared, it is impossible to know whether either is worse, the
ame, or better than no intervention at all!
In their discussion regarding beta-blocker utilization,
ung et al. (1) allege that because patients randomized to
CD therapy were disproportionately treated with beta-
lockers, the benefit of ICD therapy was accentuated.
evertheless, to overstate this point and suggest that the use
f beta-blocker therapy accounts for the difference in
urvival is inaccurate because the negative trials in Figure 1
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September 30, 2008:1122–7 ICD Benefituffered from other issues. The CABG-Patch (Coronary
rtery Bypass Graft-Patch) trial, as discussed by the au-
hors, was performed in the era of epicardial ICD
mplantation, and patients were revascularized (5). Both
he CAT (Canadian Amiodarone Therapy) trial (6) and
he AMIOVIRT (Amiodarone versus Implantable
ardioverter-Defibrillator Trial) study (7) were small and
ad event rates less than anticipated. Similarly, in the
EFINITE (Defibrillators in Nonischemic Cardiomy-
pathy Treatment Evaluation) trial, event rates were also
ower than expected (8). However, the high rate of
eta-blocker use is to be commended, and, indeed, the
ow event rate in the DEFINITE trial may be due to the
act that all patients enrolled had nonischemic cardiomy-
pathies, rather than an ischemic basis. Patients in the
INAMIT (Defibrillators in Acute Myocardial Infarc-
ion Trial) study also enjoyed high rates of beta-blocker
se, as is appropriate in the post-infarction population
9). The CIDS (Canadian Implantable Defibrillator
tudy) trial was troubled by low rates of beta-blocker
dministration (10), but was terminated early after the
esults of the AVID (Antiarrhythmics Versus Implant-
Figure 1 Major ICD Trials
Hazard ratios (vertical line) and 95% confidence intervals (horizontal lines) for de
with the non-ICD group. *Includes only ICD and amiodarone patients from CASH. A
bypass graft surgery; CASH  Cardiac Arrest Study Hamburg; CIDS  Canadian Im
Treatment Evaluation trial; DINAMIT  Defibrillator in Acute Myocardial Infarction t
ventricular ejection fraction; MADIT  Multicenter Automatic Defibrillator Implantat
nonsustained ventricular tachycardia; PVC  premature ventricular complex; SAEC
Failure Trial.ble Defibrillators) trial were
eleased (11). Finally, the
ASH (Cardiac Arrest Study-
amburg) trial was designed to
se beta-blockers in only 1 arm,
nd suffered from other prob-
ems such as interim looks at
utcomes and termination of 1
f the 4 arms prematurely (12).
To belittle the MADIT II
Multicenter Automatic Defi-
rillator Implantation Trial II)
tudy for demonstrating an abso-
ute mortality benefit of (only)
.6%, in view of the high rate of beta-blocker use and low
ate of amiodarone use, is disingenuous (13). One may argue
he degree of benefit that makes an intervention not only
tatistically significant but also clinically significant, but the
ADIT II study data speak for themselves. Are we to
gnore the results of the MADIT II study because the
egree of benefit is not more than we would like? For better
r worse, the results of the MADIT II study are the best we
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ICD Benefit September 30, 2008:1122–7ave. Furthermore, to equate a 5% increase in hospitaliza-
ion as counterbalancing a 5% decrease in mortality ignores
he point that if patients live longer and quality of life can be
reserved, the “trade” for hospitalization will be accepted by
any patients (14).
Tung et al. (1) suggest that while ICDs may not be
xpected to reduce nonarrhythmic death, they should not
ncrease nonarrhythmic deaths “as a side effect.” One can
lso easily make the argument that by preventing sudden
eath, the relative incidence of nonarrhythmic death would
ecessarily be increased as patients live longer free of
rrhythmic mortality. Rather than being seen as a negative
spect of the DINAMIT study, the observation of increased
onarrhythmic death may simply reflect that the deaths in
atients enrolled in the DINAMIT study were inevitable
rrespective of ICD therapy (9,15). Specifically, that death
as “confined only to those that received ICD discharges”
eems to indicate that for those destined to die, the final
ode of exodus can be either heart failure or arrhythmia. If
ardiac arrest occurs first, heart failure death would not have
he opportunity to become manifest. Conversely, if heart
ailure takes a patient’s life, that individual would no longer
ave the opportunity to have a cardiac arrest. To say that
CD shocks in a DEFINITE substudy “increased risk from
onarrhythmic death” does not take into account that the
rrhythmia itself may have simply been a marker for
mpending death.
While it is true that benefit in patients with nonischemic
ardiomyopathies was not significant in a certain subgroup
nalyses in the SCD-HeFT (Sudden Cardiac Death in Heart
ailure Trial) study (16), it is incorrect to state that “the
onsignificant benefit in nonischemic cardiomyopathy sub-
roup analysis was implemented into guidelines, and lack of
enefit in NYHA functional class III patients was left out” (1).
ndeed, the SCD-HeFT study conclusion in aggregate was
hat was incorporated in the guidelines (i.e., benefit was
fforded to all patients who met enrollment criteria). This is in
eeping with standard application of clinical trials and not
cherry picking” subgroups for inclusion and exclusion from
ecommendations.
In trials of secondary prevention, the fact that the CIDS
10) and CASH (12) trials failed to demonstrate significant
eductions in mortality by ICD therapy can be explained by
ome of the reasons addressed in the previous text. Further-
ore, the CIDS trial was discontinued early because the
VID trial results were positive, and continuing the trial
ould have been inappropriate. In view of the AVID trial
esults (11), the trend in the CIDS trial (10), and the
eta-analysis combining the AVID, CIDS, and CASH
17) trials, it is reasonable to conclude that the benefit of
CD therapy in high-risk patients with resuscitated ventric-
lar arrhythmias is consistent, and arguably modest. The
vidence supports the use of ICD therapy for secondary
revention (Fig. 1). cs There Discordance Between Evidence
nd Guidelines in the Post-Infarction Setting?
ung et al. (1) are correct that the ventricular arrhythmia
uideline invoked a left ventricular ejection fraction
LVEF) cutoff of 0.40 for ICD implantation. The new
evice-Based Therapy Guidelines, however, addressed
his disconnect between the evidence base and recom-
endations and adopted a more trial-based approach.
pecifically, the guidelines now “. . . acknowledge that the
ACC/AHA/ESC 2006 Guidelines for Management of
atients With Ventricular Arrhythmias and the Prevention
f Sudden Cardiac Death’ used an LVEF of less than 40%
s a critical point to justify ICD implantation for primary
revention of SCD. The LVEF used in clinical trials
ssessing the ICD for primary prevention of SCD ranged
rom less than 40% in MUSTT (Multicenter Unsustained
entricular Tachycardia Trial) to less than 30% in MADIT
I (Multicenter Automatic Defibrillator Implantation Trial
I). Two trials, MADIT I (Multicenter Automatic Defi-
rillator Implantation Trial I) and SCD-HeFT (Sudden
ardiac Death in Heart Failure Trial), used LVEFs of less
han 35% as entry criteria. The present writing committee
eached the consensus that it would be best to have ICDs
ffered to patients with clinical profiles as similar to those
ncluded in the trials as possible. Having given careful
onsideration to the issues related to LVEF for these
pdated ICD guidelines, we have written these indications
or ICDs based on the specific inclusion criteria for LVEF
n the trials. Because of this, there may be some variation
rom previously published guidelines” (2).
Tung et al. (1) overstate that the findings of the
INAMIT study (9) contradict the inferences from the
ALIANT (Valsartan in Acute Myocardial Infarction
rial) study (18). Although the VALIANT study did
how a high early post-infarction risk for sudden death,
here is no evidence that these patients would have been
aved by an ICD. As in the DINAMIT trial, these very
atients may have been destined to die irrespective of any
good) therapy provided (15). Conversely, though many
atients enrolled in the MADIT II study had their
nterval index myocardial infarction over 6 years before
nrollment, analysis of the data did indicate that survival
enefit was durable many years after infarction (19).
ave Adverse Effects on Morbidity, Quality
f Life, and Proarrhythmia Been Underestimated?
he fact that ICD therapy is not a surrogate for resuscita-
ion from cardiac arrest is not new information. A 1993
olicy conference from the North American Society of
acing and Electrophysiology concluded that “total mortal-
ty” was, in fact, the “appropriate” end point for reporting
CD outcomes (20). While the examples Tung et al. (1)
rovided regarding the “dark side” of ICD therapy are
orrect, ICDs can have proarrhythmic effects, negative
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September 30, 2008:1122–7 ICD Benefitffects on quality of life, and malfunction, they do not
egate the results of studies that in the aggregate show
enefit. Tung et al. (1) emphasized the importance of
alking to patients. I could not agree more: more than once
have said that we need to return to treating patients
ather than ejection fractions! But to point to the
OMPANION (Companion of Medical Therapy, Pacing
nd Defibrillation in Heart Failure) trial (21) data, which
hows a 2% higher incidence of sudden death in the cardiac
esynchronization therapy (CRT) arm compared with that
n the control arm, ignores the often observed choice of
atients to “trade” improved quality of life for sudden
eath, when given the choice (14). Indeed, it is the
xperience of many clinicians that when given a choice,
atients would much prefer quality of life with earlier
eath rather than prolonged survival with markedly
mpaired quality of life (14). Indeed, all CRT trials have, in
he aggregate, shown both decreased mortality and im-
roved quality of life, even though the incidence of sudden
eath may be increased, perhaps because patients have lived
onger without heart failure and arrhythmic death has
eplaced heart failure death. The new guidelines repeatedly
dvise that “all primary SCD prevention ICD recommen-
ations apply only to patients who are receiving optimal
edical therapy and have reasonable expectation of survival
ith good functional capacity for more than one year” (2). A
ection that focuses on heart failure after first appropriate
CD therapy concludes that “to maximize the benefit after
sudden death has been prevented, it is crucial that the
anagement team evaluate the heart failure profile, review
he medical regimen, and plan for ongoing care” (2).
The ICD’s impact on quality of life is influenced by
hether or not shock therapy is delivered. However, Hsu
t al. (22) observed that simply having survived a life-
hreatening ventricular arrhythmia has a negative impact.
owever, Hsu et al. (22) also found that after therapy, most
atients had improvement, indeed possibly more so in those
reated with an ICD. In the AVID study, although shocks
ere associated with decreased quality of life, ICD and
ntiarrhythmic drug therapy were overall associated with
imilar alterations in self-perceived quality of life (23). In
he CIDS trial, quality of life was better with an ICD than
ith amiodarone (24). And in the DEFINITE trial, quality
f life was not affected by ICD implantation undertaken for
rimary prevention (25).
Regarding hardware malfunction, there are probably
any reasons why the ICD market has flattened. Decreased
CD implantation rates were caused not only by recalls, but
ossibly also by the vigorous application of ICD therapy to
large reservoir of patients with ICD indications that has
een emptied over the last several years. Furthermore,
xperienced clinicians all know that when a new therapy is
eleased there is a rush to implement it, whether it be a drug
r device, followed by a swinging of the pendulum back
oward the midline. It is my belief that the reservoir and
endulum issues were just as strong in affecting the ICD tarket as has been the occurrence of recalls. The new
uidelines include a section in ICD follow-up addressing
omplications, device and lead failures, and management
trategies. An entire section is entitled “Impact on Quality
f Life (Inappropriate Shocks)” (2).
as ICD Cost-Effectiveness Been Overstated?
ost-effectiveness analysis is one of the most difficult
spects of any therapy to assess; indeed, a discipline has
volved to address this need. Since many assumptions are
ade when undertaking these analyses, the arguments of
ung et al. (1) are well taken. As such, in the 2002 Guidelines
26), the writing committee did not overstate ICD cost-
ffectiveness. The limitations of mathematical modeling and
onrandomized studies to estimate cost-effectiveness were
ddressed. We specifically indicated that ICD cost-
ffectiveness would be greatest in patients at high risk of
rrhythmic death and at low risk for other causes of death.
e also stated that cost-effectiveness would be improved by
owering the cost of the device and improving reliability and
ongevity. Indeed, the guidelines anticipated the challenges
f advisories recently experienced.
Since those guidelines were published, new data have
ecome available. Although cost per life-year saved is
xpensive ($235,000 in the MADIT-II study), when the
ime horizon is extended to 12 years, the cost decreases to
78,600 to $114,000 per life-year saved (27). Others have
ome to similar conclusions (28,29).
The new guidelines incorporate a section similarly ad-
ressing cost-effectiveness (2). It begins by stating, “Long
erm follow-up studies have consistently demonstrated that
umulative medical costs are increased substantially among
atients receiving an ICD.” It goes on to say that patient
election is necessary for ICD implantation to be cost-
ffective, and that when restricted in this manner, cost-
ffectiveness may be similar to other accepted cardiovascular
herapies and compare well to the benchmark of renal
ialysis ($30,000 to $50,000 per year of life saved). In short,
he guidelines recognize that ICD implantation will be
ore cost-effective when used for patients at high risk of
rrhythmic death and at low risk of other causes of death.
he cost section concludes with an acknowledgement that
or CRT, cost-effectiveness has not been evaluated (2).
esolution and the Future
ung et al. (1) treat every negative observation or subgroup
omparison in the ICD groups as absolute truth, while on
he other side, they criticize or belittle every positive
bservation or comparison. Although, like all clinical trials,
hose evaluating ICD therapy have limitations, from the
erspective of evidence-based medicine, there are few inter-
entions that in multiple trial settings have consistently over
10-year period produced a 20% to 30% reduction in total
ortality (Fig. 1). ICD therapy has done just that. We needo use this powerful tool in the most appropriate manner
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ICD Benefit September 30, 2008:1122–7ased on the guidelines that resulted from the trials. I have
ot addressed each point discussed by Tung et al. (1), but
ould stress that guideline committees do look at and weigh
he universe of data. Although we all freely admit that there
re problems with ICDs, the weight of evidence supports
heir use for the indications listed in appropriate patients.
urthermore, if follow-up is adequately funded, the Na-
ional Cardiovascular Data Registry has the opportunity to
rovide data and help guide future clinical decisions.
Practice guidelines are developed according to a formal
rocess of review of evidence by multiple experts to provide
ecommendations regarding therapy, including discussions
ith patients as well as pharmacologic and device-based
herapies. The 2008 Device-Based Therapy Guidelines (2)
onsidered the same evidence base and came up with similar
ecommendations with a different group of experts weighing
ll of the clinical evidence (30). The “opinions” Tung et al.
1) present are just that—“opinions” of a small group of
ndividuals. By contrast, the 2008 Device-Based Therapy
uidelines (2), like the 2006 Ventricular Arrhythmia
uidelines (30), represent the results of a robust process of
valuating all evidence by 2 independent groups of experts,
ormal review by other experts, and final approval by the
overning boards of the Heart Rhythm Society, American
ollege of Cardiology, and American Heart Association.
his process legitimizes guidelines, and therefore, they carry
he full weight of organizational endorsement behind them.
Finally, yes, there is a dark side to ICD therapy. Devices
ail, and in unpredictable subsets, especially patients who get
nappropriate shocks, quality of life is decreased. Unfortu-
ately, life is not perfect. Thus, the Heart Rhythm Society
as taken the opportunity of confronting the “dark side” of
CD therapy, especially in regard to device and lead mal-
unction, and developed guidance documents on responsible
eporting and how industry should handle observations on
evice function (31).
It is my hope, as indicated in the final section of the
008 Device-Based Therapy Guidelines, that research
ill be undertaken to help identify not only patients who
ould be the most likely to benefit from ICD therapy,
ut also those expected not to benefit (2). Retrospective
nalyses have already shown that this may be possible
32,33), and trials are in progress in this regard. Already
pecific patient populations are now recognized for whom
he benefit of ICD therapy outweighs any risks (2). But,
ntil data are available that may reliably allow us to more
recisely focus the prescription of ICD therapy to patients
ho may benefit most and avoid adverse effects on quality of
ife, we are left with the results of clinical trials that in the
ggregate show improved survival in a broad selection of
atients with left ventricular dysfunction and either demon-
trated or anticipated risk for arrhythmic death. Evidence-
ased medicine, the rigorous process of guideline writing,
eview, and approval, and the ethical consideration of offering
roven life-prolonging therapies to all patients, provide a
1ompelling rationale for the clinician to carefully consider the
uidelines in their clinical decision making.
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